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Mutations in hedgehog signaling pathway genes,
especially PTC1 and SMO, are pivotal to the devel-
opment of basal cell carcinomas. The study of basal
cell carcinoma gene expression not only may eluci-
date mechanisms by which hedgehog signaling
abnormalities produce aberrant tumor cell behavior
but also can provide data on in vivo hedgehog target
gene control in humans. We have found, in compari-
son with normal skin, that basal cell carcinomas have
increased levels of mRNA for PTC1, GLI1, HIP,
WNT2B, and WNT5a; decreased levels of mRNA for
c-MYC, c-FOS, and WNT4; and unchanged levels of
mRNA for PTC2, GLI2, WNT7B, and BMP2 and 4.
These ®ndings suggest that mutations in hedgehog
signaling pathway genes may exert both cell autono-
mous and indirect effects and indicate that basal cell
carcinoma tumor cells have a phenotype that at least
in some aspects resembles that of epidermal stem
cells. Key words: GLI/PTC/signaling/skin carcinogenesis.
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B
asal cell carcinoma (BCC), although the commonest
human cancer, had been subjected to relatively little
molecular analysis until several years ago, when
heritable mutations in PATCHED1 (PTC1) were
found to underlie the basal cell nevus syndrome (MIM
no. 109400) (Hahn et al, 1996; Johnson et al, 1996), a rare
autosomal dominant af¯iction characterized by multiple phenotypic
abnormalities, including the development of multiple BCC starting
in youth. PTC1 inhibits signaling by the membrane protein
Smoothened (Smo), and this inhibition is relieved by binding Sonic
Hedgehog (SHH) to PTC. Unrestricted Smo signaling can affect
target gene transcription via the GLI family of transcription factors
(GLI1, GLI2, and GLI3). PTC1 is itself a target for HH signaling,
thus forming a feedback loop in which decreased PTC1 protein
function leads to the production of more PTC1 mRNA. In BCC,
the feedback loop is disrupted because the increased mRNA
encodes a nonfunctional PTC1 protein, and indeed PTC1 mRNA,
as well as SMO, GLI1, and GLI3 mRNA, have been reported to
accumulate in BCC. Other genes whose expression has been
described to be activated by HH signaling in various tissues include
members of the WNT/Wg and BMP/TGFb families of signaling
molecules and the gene encoding the cell-surface HH-binding
protein HIP (Dahmane et al, 1997; Ingham, 1998; Chuang and
McMahon, 1999; Ghali et al, 1999).
So far, it remains unclear how mutations in PTC1 and SMO and
consequent changes in HH target gene expression produce the
abnormal proliferation, differentiation, and adhesion characteristic
of BCC tumor cells. As part of an effort to investigate this question,
we have surveyed BCC for in vivo quantitative abnormalities of
mRNA encoding hedgehog target genes, hemidesmosomal
proteins, and a selection of genes that encode proteins important
in apoptosis and cell cycle regulation.
MATERIALS AND METHODS
Aliquots of nodular BCC removed from the skin by curettage and
normal human skin (obtained as part of breast reduction surgery) or
epidermis (the roof of suction blisters of the volar forearm) were frozen
immediately in liquid nitrogen and were stored at ±70°C until assayed or
were ®xed and processed for routine microscopic examination. We used
a Qiagen RNAeasy kit (Qiagen, Valencia, CA) to extract RNA from
these tissues and from cultured normal cells [precon¯uent epidermal
keratinocytes (HEK) grown in 0.07 mM Ca2+ and ®broblasts] and cell
lines (HaCaT, HeLa, and D259MG). mRNA for PTC1, PTC2, GLI1,
c-MYC, HIP, and GAPDH was quantitated by TaqMan. Primer and
probe sequences are available as follows: Patched 1: forward (5¢-TCT
TCA TGG CCG CGT TAA TC-3¢), reverse (5¢-TTG CAG GAA AAA
TGA GCA GAA C-3¢), probe (5¢-FAM-AAT TCC CGC TCT GCG
GGC G-TAMARA-3¢); Patched 2: forward (5¢-CCA GCA CCC
CCT CAT CAG-3¢), reverse (5¢-GAC CCG AAG ACC AAT TCA
GC-3¢), probe (5¢-FAM-CAC AAG GAG CGC CAC TGT CTG
GAC-TAMARA-3¢); GLI1: forward (5¢-TGA GGC CCT TCA AAG
CCC-3¢), reverse (5¢-GTA TGA CTT CCG GCA CCC TTC-3¢),
probe (5¢-FAM-TGC TGG TGG TTC ACA TGC GCA GA-TAM-
ARA-3¢); HIP: forward (5¢-TGC TAA GCC TCG CAT TCC A-3¢),
reverse (5¢-ACA ACC CTA AGA ATG TGG TCA TGA-3¢), probe (5¢-
FAM-TGT ATG TGT CCT ATA CCA CCA ACC AAG AAC GG-
TA-3¢); c-Myc: forward (5¢-CAG CTG CTT AGA CGC TGG ATT-3¢),
reverse (5¢-GAG GTC ATA GTT CCT GTT GGT GAA-3¢), probe
(5¢-FAM-CTC CCG CGA CGA TGC CCC T-3¢); GADPH: forward
(5¢-GAA GGT GAA GGT CGG AGT CA-3¢), reverse (5¢-GAA GAT
GGT GAT GGG ATT TC 3¢), probe (5¢-FAM-CAA GCT TCC CGT
TCT CAG CC±TAMARA-3¢). Ribonuclease protection assays (RPA)
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were performed using the Ambion RPAII kit according to the manufac-
turer's recommendations (Ambion, Austin, TX). Probes used for RPA
were produced by polymerase chain reaction (PCR) ampli®cation of
published sequences (GLI2, INTEGRIN b4), were purchased from
Pharmingen or Ambion, or were generous gifts (PTC1, GLI1,
INTEGRIN a6, and BPAG1 and BPAG2). DNA was linearized to give
anti-sense probes of 150±300 bp and was labeled with a Promega
(Madison, WI) transcription kit. Gels were scanned for quantitative
densitometry using a BioRad (Hercules, CA) Model GS-670 imaging
densitometer. The relative levels of three controls (``housekeeping'' genes
± GAPDH, ACTIN, and CYCLOPHILIN) were consistent in each
sample, suggesting that none of the three changed signi®cantly in these
samples. We identi®ed WNT family members expressed in HEK and in
BCC by reverse transcription±PCR ampli®cation using consensus WNT
family primers: forward (5¢-GGG GAA TTC CAR GAR TGY AAR
TGY CAY-3¢, reverse (5¢-AAA ATC ATC TAG ARC ARC ACC
ART GRA A-3¢) (Gavin et al, 1990).
RESULTS
PTC Levels of PTC1 mRNA in all 27 BCC studied were
elevated markedly compared with controls (epidermis, skin, or
HEK) with a 15-fold variation among individual tumors. Levels
were 10±500-fold higher by TaqMan and up to 1600-fold higher
by RPA; however, PTC1 expression in the controls was very low,
and consequently precise quantitation by RPA was dif®cult. Like
those of PTC1, levels of PTC2 mRNA were high in BCC and
were low in HEK; however, unlike those of PTC1, levels of PTC2
mRNA also were high in normal epidermis. Cultured dermal
®broblasts and HaCaT cells had uniformly low levels of PTC1
(albeit higher than the levels in HEK) and of PTC2 mRNA.
D259MG cells, the cell line from which ampli®ed GLI1 originally
was isolated, had low levels of PTC2 mRNA but, unlike other
cultured cells studied, had elevated levels of PTC1 mRNAÐas
high as those in BCC (Table I).
GLI Levels of GLI1 message were elevated (vs that in HEK or
skin) in all 12 BCC studied by TaqMan, the average level being
approximately 1/6 that in D259MG cells (Table I). In seven BCC
studied by RPA, levels of GLI2 varied over a 9-fold range, were
absent in HEK and in D259MG cells, but were as high in skin as in
BCC.
HIP Of ®ve BCC tested by RPA three had mRNA levels 10-
fold increased, and two had levels approximately 100-fold increased
vs those in HEK. The levels in the two latter BCC were similar to
that in D259MG cells. HIP expression was undetectable by RPA in
extracts of normal skin (Fig 1). In ®ve BCC tested by TaqMan,
HIP expression averaged 40-fold higher than in normal skin and
nearly 300-fold higher than in epidermis or HEK (Table I).
WNT genes By cloning reverse transcription±PCR product
prepared from RNA, we found ®ve different WNT family
members (2, 2b, 4, 5a, and 7b) to be expressed in cultured HEK
and/or BCC, of which WNT7b was found the most commonly.
By RPA WNT2b and 5a were undetectable to very low in HEK
and skin but clearly were expressed in BCC, albeit at varying levels.
By contrast, WNT4 was expressed in epidermis and skin but not in
BCC (or in HEK). WNT7b was detected readily in all BCC,
epidermis, and skin but was undetectable in HEK. WNT2
expression was highly elevated in one of ®ve BCCs studied but
was undetectable by RPA in HEK.
c-MYC Of eight BCC tested by RPA all had near-complete loss
of c-MYC mRNA as compared with that in HEK, epidermis, or
whole skin. D259MG cells also have low c-MYC mRNA, whereas
levels in HeLa and HaCaT cells are at least as high as those in HEK
(Fig 2). With Taqman, c-MYC expression is very high in epidermis
and at least 15-fold lower in BCC (Table I).
BMP mRNA for BMP2 and BMP4 were detectable at similar
levels in BCC, skin, and epidermis. BMP2 and BMP4 expression
levels were absent to very low in HEK.
Hemidesmosomal protein gene expression We assessed
mRNA levels of the four major known components of
hemidesmosomes in BCC. mRNA for BPAG1 and BPAG2
were readily detectable in BCC and were present at levels similar to
those in HEK or whole skin. a6 and b4 integrin mRNA are visible
Table I. PTC1, PTC2, and GLI1 expression in BCC mRNA levels were measured by TaqMan analysis and were
normalized to the expression levels of GAPDHa
PATCHED 1 PATCHED 2 GLI1 c-MYC HIP
HEK 0±0.14 0.1±0.5 0.007±0.2 17 0±0.05
Epidermis 0±0.59 11 0.1 94±99 0±0.01
Normal skin 0±2.2 1.6±62 (av. 18) 0.7±1.7 21 0.04
BCC 2±100 (av. 18) 2.3±54 (av. 17) 7±102 (av. 41) 0.8±14 (av. 6) 0.1±3.6 (av. 1.4)
D259MG 7±11 0.2 275 ND ND
aValues in the table are (2^Delta CT) *100 and, for BCC, represent 12±20 individual tumors for PATCHED 1, PATCHED 2, and GLI1 and ®ve tumors for c-MYC
and HIP.
Figure 1. RNase protection assay of HIP expression in BCC and
in control samples.
Figure 2. RNase protection assay of c-MYC
expression in BCC and in control samples.
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as faint bands in RPA of extracts of BCC, normal skin, or epidermis
and are expressed at much higher levels in HEK. The single BCC
with high a6 integrin expression did not differ clinically or
histologically from those with lower expression.
Other Levels of expression of several genes involved in cell cycle
regulation (p53, Rb, p21, and cdk4) and in control of apoptosis (bclx,
bax, and mcl) varied among individual tumors and were not
markedly different from those of skin. One consistent change seen
was an at least 100-fold decrease in mRNA for c-FOS in BCC
(n = 8) vs in normal skin (Fig 3), a ®nding that is consistent with
previous reports of high levels of c-FOS expression in adult human
skin, especially in suprabasal cells, and reduced levels in BCC
(Basset-Seguin et al, 1990; Takahashi et al, 1994).
DISCUSSION
These data are consistent with the growing evidence that hedgehog
target gene activation is the pivotal step in BCC carcinogenesis and
is the ®rst study of the levels of expression of GLI2, WNT, BMP, c-
MYC, and HIP in BCC. Furthermore, we have generated
quantitative data regarding the degree to which the message for
three HH-regulated genes accumulate in these tumors: PTC1,
GLI1, and HIP mRNA levels are at least 50±100-fold increased
in vivo in BCC; levels that we have found to be matched in vitro
only by the levels in D259MG cells, in which GLI1 is highly
ampli®ed. The uniformity of this upregulation of PTC1 mRNA in
BCC indicates that loss of PTC1 protein function rarely is due to
deletions of both genomic copies, production of unstable mRNA,
or prevention of transcription of PTC1 message. The PTC2 levels
that we detected con®rm those seen by in situ hybridization
(Carpenter et al, 1998; Zaphiropoulos et al, 1999). The lack of
upregulation of PTC2 expression by ampli®ed GLI1 in D259MG
cells, like the maintenance of PTC2 expression in the lung and skin
of Shh ±/± mouse embryos (Pepicelli et al, 1998; St-Jacques et al,
1998), is consistent with the conclusion that, at least in these tissues,
PTC2 expression is not an HH target gene. Overexpression of
GLI1 or GLI2 in the epidermis of transgenic mice can drive the
development of BCC (Grachtchouk et al, 2000; Nilsson et al,
2000). Our ®nding of levels of GLI1 that were upregulated
consistently, of levels of GLI2 mRNA that were less consistent and
on average were no higher than in normal skin, and of stronger
RPA bands with GLI1 than GLI2 all suggest that GLI1 may be
more important in vivo in driving the aberrant cell behavior
characteristic of BCC. We have no information, however,
regarding possible post-translational activation of these proteins in
epidermis, and so the primacy of GLI1 must be considered a
tentative conclusion.
HIP is a gene recently identi®ed in a cell-free screen for murine
genes encoding proteins that bind Shh. It is present at the cell
surface where it binds Shh with an avidity similar to that of PTC1,
is a transcriptional target of Shh signaling during mouse develop-
ment, and appears to attenuate Shh signaling, most likely by binding
Shh and thereby reducing its interaction with Ptc1 (Ingham, 1998).
Our ®nding of high levels of HIP mRNA in BCC indicates that its
expression is an in vivo target of HH signaling in humans as well as
in mice.
The repertoire of WNT genes expressed in adult human
epidermis has not previously been explored systematically. Saitoh
et al (1998) analyzed WNT expression in adult murine epidermis
using a strategy similar to ours: cloning of PCR product ampli®ed
from WNT consensus primers followed by RPA quantitation.
They found clones of Wnt4, 7a, and 10b, expression only of Wnt4
and 10b in epidermis, and of Wnt4 in newborn mouse epidermal
keratinocytes in culture. We cloned sequences corresponding to
WNT2b, 4, 5a, and 7b from cDNA prepared from cultured HEK
and to WNT2, 2b, 4, 5a, and 7b from cDNA prepared from BCC.
Levels of WNT2 expression measured by RPA were low to
undetectable in HEK. Expression of WNT2b, 5a, 7b and 13 were
readily detectable in BCC. Human (like mouse epidermis) does
express WNT4 but this WNT is undetectable in BCC. As the bulk
of the cells in these samples were tumor cells, most likely the WNT
messages detected in BCC were derived from the malignant cells
rather than from ``contaminating'' normal stromal cells, but
con®rmation of this conclusion must await in situ studies. The
expression of multiple WNT genes detectable at low levels by RPA
is reminiscent of reports of similar studies in breast cancers (Huguet
et al, 1994), and different WNT have been described as having
varying transforming potencies (Wong et al, 1994).
One intracellular pathway by which Wnt signaling proceeds is
via stabilization of b-catenin, which interacts with the Tcf-Lef
family of transcription factors to affect gene expression.
Stabilization of b-catenin protein by mutations in the b-catenin
gene in keratinocytes produce pilomatrixomas, a skin tumor
distinct from BCC (Chan et al, 1999). Stabilization of b-catenin
protein in colon cancer cells, often by mutations in APC, is
associated with upregulation of c-MYC expression (He et al, 1998).
In contrast, despite their upregulation of WNT2b and 5a and hence
potential b-catenin stabilization, we have found that BCC have c-
MYC downregulation as compared either to skin or to cultured
normal HEK. Different WNT species clearly affect the phenotype
of cells differently, as manifested both by their different patterns of
expression in normal vs malignant cells and also by their differing
abilities to stabilize b-catenin and to transform, e.g., mammary
epithelial cells in which speci®c model WNT4, 5a, and 7b have no
effect (Shimizu et al, 1997), and it is possible that different WNT
produce different effects on c-MYC expression as well.
BCC have been suggested to arise from epidermal stem cells that
are located in the bulge region of the hair follicles. That postulate is
based not only on the continued proliferation and resistance to
differentiation of BCC cells but also on their frequent expression of
antigens similar to those expressed by the cells of the hair follicle
bulge region, e.g., keratins 15 and 19 and a2, a3, and b1 integrins.
Also consistent with this view is the observation that ptc +/± mice
have upregulation of ptc promoter activity in the bulge cells as well
as in BCC (Aszterbaum et al, 1999). Epidermal stem cells express
low levels of c-MYC despite their relatively high levels of b-catenin
protein and despite the ability of exogenous stabilized b-catenin to
enhance stem cell numbers in vitro (Zhu and Watt, 1999).
Upregulation of c-MYC expression can drive human epidermal
stem cells into a transient amplifying phenotype (Gandarillas and
Watt, 1997), and most but not all studies report that c-MYC
expression then is downregulated coincident with the onset of
keratinocyte terminal differentiation. Consistent with these ®nd-
ings, c-MYC expression in transgenic mice recently was found to
drive epidermal keratinocyte proliferation and to inhibit normal
complete differentiation in vivo (Pelengaris et al, 1999; Waikel et al,
1999). Hence, at least in their failure to switch from proliferation to
differentiation and their downregulation of c-MYC, BCC resemble
epidermal stem cells. Of note, however, the putative epidermal
stem cells of the hair follicle bulge, unlike BCC, do express a6 and
b4 integrins and bullous pemphigoid proteins. Thus we speculate
that upregulation of expression of WNT2b and/or 5a (and/or
downregulation of WNT4 expression) and a possible resultant
downregulation of c-MYC expression may be a crucial pathway by
Figure 3. RNase protection assay of c-FOS expression in BCC
and in control samples.
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which hedgehog target gene dysregulation produces at least some
aspects of the BCC phenotype.
Our quantitation of hemidesmosomal protein mRNA levels
suggests that the well-established loss of hemidesmosomal proteins
in BCC may not be controlled by loss of mRNA for integrins a6
and b4 or BPAG1 or 2. However, in contrast to our results, others
have found consistent loss of BPAG1 and 2 mRNA by reverse
transcription±PCR in BCC (Chopra et al, 1998).
The marked differences in gene expression between cultured and
in situ keratinocytes complicate the choice of proper controls.
Further, these differences are consistent with other data indicating
that the response of cultured cells to the hedgehog ligand or to the
loss of PTC is blunted (Fan et al, 1997). Our ®nding of upregulated
PTC1 and HIP in cells with ampli®ed GLI1 (D259MG cells)
suggests that the block to the hedgehog response in cultured cells
lies upstream of this transcription factor.
These ®ndings further validate the concept of the primary role of
hedgehog target gene activation in BCC tumorigenesis and are
consistent with previously elucidated pathways of hedgehog
signaling. Considerably more work, however, will be necessary
to elucidate which of these changes described or which other
changes yet to be described will be found to be the key to the
mechanism by which aberrant hedgehog signaling leads to aberrant
BCC cell behavior and which will be found to be epiphenomena.
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